Literature DB >> 7485699

Murine immunoglobulin G subclass responses following immunization with live dengue virus or a recombinant dengue envelope protein.

J J Smucny1, E P Kelly, P O Macarthy, A D King.   

Abstract

Murine immunoglobulin G (IgG) subclass responses to immunization are restricted to certain subclasses depending on the nature of the immunogen. Immunization with live viruses generally leads to a predominant IgG2a response, which may be the most effective at resisting future challenge due to the unique effector functions of IgG2a. Knowledge of subclass responses following immunization with dengue vaccine candidates may be helpful in determining which candidates are most efficacious. We measured the dengue-specific IgG subclass responses of BALB/c mice following immunization with live dengue-2 virus or with a partially purified recombinant dengue-2 envelope (E) protein. Subclass responses following immunization with live virus were IgG2a > IgG1 > IgG2b > IgG3, as opposed to IgG1 > IgG2a > IgG2b > IgG3 after immunization with recombinant protein. Responses of all subclasses except IgG1 were greater following immunization with live dengue than with the recombinant E protein. Neutralizing antibody titers were also higher after immunization with live virus than with E protein and were positively correlated with dengue-specific IgG2a responses in mice immunized with recombinant E protein. Following separation of the four IgG subclasses by chromatography, the IgG2a fraction exhibited the greatest neutralizing activity. The results seen after immunization with live dengue virus or recombinant E protein in this study are in concordance with studies involving other viruses and viral proteins and may have implications for the development of an effective vaccine for dengue.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7485699     DOI: 10.4269/ajtmh.1995.53.432

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

1.  Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.

Authors:  Judith H Aberle; Stephan W Aberle; Regina M Kofler; Christian W Mandl
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.

Authors:  Laurent Gros; Hanna Dreja; Anne Laure Fiser; Marc Plays; Mireia Pelegrin; Marc Piechaczyk
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 3.  Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.

Authors:  Alan L Rothman
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

Review 4.  Latest developments and future directions in dengue vaccines.

Authors:  Usa Thisyakorn; Chule Thisyakorn
Journal:  Ther Adv Vaccines       Date:  2014-01

5.  Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis.

Authors:  Douglas M Watts; Robert B Tesh; Marina Siirin; Amelia Travassos da Rosa; Patrick C Newman; David E Clements; Steven Ogata; Beth-Ann Coller; Carolyn Weeks-Levy; Michael M Lieberman
Journal:  Vaccine       Date:  2006-08-22       Impact factor: 3.641

6.  Evaluation of the safety and adjuvant effect of a detoxified listeriolysin O mutant on the humoral response to dengue virus antigens.

Authors:  K G Hernández-Flores; A L Calderón-Garcidueñas; G Mellado-Sánchez; R Ruiz-Ramos; L A Sánchez-Vargas; P Thomas-Dupont; I Y Izaguirre-Hernández; J Téllez-Sosa; J Martínez-Barnetche; L Wood; Y Paterson; L Cedillo-Barrón; O López-Franco; H Vivanco-Cid
Journal:  Clin Exp Immunol       Date:  2017-01-19       Impact factor: 4.330

7.  Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants.

Authors:  Dominique Markine-Goriaynoff; Jean-Paul Coutelier
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

8.  Use of pre-S protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection.

Authors:  Jung Sun Yum; Byung Cheol Ahn; Hyun Jin Jo; Dong Yeon Kim; Ki Hyun Kim; Hyo Sun Kim; Young Chul Sung; Jaeseung Yoon; John Morrey; Hong Mo Moon
Journal:  Clin Vaccine Immunol       Date:  2011-12-07

Review 9.  A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies.

Authors:  Muhammad Faheem; Ummar Raheel; Muhammad Nasir Riaz; Naghmana Kanwal; Farakh Javed; Najam us Sahar Sadaf Zaidi; Ishtiaq Qadri
Journal:  Mol Biol Rep       Date:  2010-11-24       Impact factor: 2.316

10.  Reactivity of DENV-positive sera against recombinant envelope proteins produced in bacteria and eukaryotic cells.

Authors:  Higo Fernando Santos Souza; Arthur Baruel Zaneti; Bianca da Silva Almeida; Jéssica Amaral Martinho; Márcio Massao Yamamoto; Daniela Santoro Rosa; Renata Denzegrini Slhessarenko; Silvia Beatriz Boscardin
Journal:  Immunol Res       Date:  2022-10-03       Impact factor: 4.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.